Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06704152 · ClinicalTrials.gov registry record · Phase 1
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
A Phase 1 study of MDS and AML, Adult Recurrent, sponsored by BlueSphere Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT06704152: Recruiting Phase 1 study of MDS and AML, Adult Recurrent, sponsored by BlueSphere Bio.
NCT06704152 is a Phase 1 study of MDS and AML, Adult Recurrent that is actively recruiting participants, run by BlueSphere Bio. The registered enrollment target is 38 participants, below the 95-participant average among 22 other MDS trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06704152, a Phase 1 study of MDS and AML, Adult Recurrent, is actively recruiting participants, sponsored by BlueSphere Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Primary Outcome
Incidence of TEAEs (per Common Terminology Criteria for Adverse Events \[CTCAE\])
Conditions Studied
Interventions
- DRUG SOC + BSB-1001 Dose Escalation Cohort
- DRUG SOC+BSB-1001 Expansion Dose
Study Locations (6)
California
- City of Hope National Medical Center - Duarte
Florida
- Moffitt Cancer Center - Tampa
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University at St Louis - St Louis
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT06704152 shows while recruiting
NCT06704152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 95-participant average among 22 other MDS trials with a reported enrollment target (60% lower).
The record links to 3 conditions, with MDS appearing as the primary indexed condition, and to 2 interventions - of which SOC + BSB-1001 Dose Escalation Cohort is the first listed.
NCT06704152 lists 6 locations in 6 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06704152 about?
NCT06704152 is a clinical study titled "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS". The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
What is the current status of trial NCT06704152?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-02-04. Estimated completion is 2029-03.
What conditions does trial NCT06704152 study?
This clinical trial studies the following conditions: MDS, AML, Adult Recurrent, ALL, Recurrent, Adult.
What interventions are being tested in trial NCT06704152?
The interventions under investigation include: SOC + BSB-1001 Dose Escalation Cohort (DRUG), SOC+BSB-1001 Expansion Dose (DRUG).
Who is sponsoring clinical trial NCT06704152?
This trial is sponsored by BlueSphere Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06704152 being conducted?
This trial has 6 study locations across California, Florida, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06704152's enrollment target sits among peer trials
38 12th of 22 higher than 11 of 22 other MDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other MDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI